FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

مكتبة الأكواد

NAD+ Restoration

Anti-Aging & Longevitybeginner

76

التعاون

76
Share
البروتيدات

2

متوسط الجرعة اليومية (mcg)

76,429

المستوى

beginner

تمت الإضافة

May 17, 2026

نظرة عامة

The NAD+ Restoration stack combines senolytic therapy with direct NAD+ replenishment to address two interconnected hallmarks of aging: cellular senescence and metabolic cofactor depletion. FOXO4-DRI is a D-retro-inverso peptide that disrupts the interaction between FOXO4 and p53 in senescent cells. Normally, FOXO4 sequesters p53 in the nucleus of senescent cells, preventing them from undergoing apoptosis. By competitively binding FOXO4, the DRI peptide frees p53 to trigger apoptotic pathways specifically in senescent cells — those dysfunctional cells that accumulate with age and secrete inflammatory factors (SASP) that damage surrounding healthy tissue. In the landmark 2017 study by Baar et al. published in Cell, FOXO4-DRI administration to aged mice restored fitness, fur density, and renal function by selectively clearing senescent cells. This represents a true senolytic mechanism — killing aged cells rather than trying to rejuvenate them. The D-retro-inverso modification makes the peptide resistant to proteolytic degradation, giving it extended biological activity. NAD+ intravenous infusion provides direct restoration of this critical coenzyme, bypassing the multi-step oral conversion pathway (NMN → NAD+ requires enzymatic steps that may be rate-limited in aging tissues). NAD+ is required for sirtuin activation (SIRT1-7), PARP-mediated DNA repair, mitochondrial electron transport, and circadian clock function. The combination logic is that clearing senescent cells (FOXO4-DRI) removes the source of inflammatory signaling that depletes NAD+ in neighboring cells, while NAD+ infusion restores the metabolic capacity of remaining healthy cells. This represents a cutting-edge research protocol — FOXO4-DRI has no human clinical trials, and the stack should be understood as experimental and hypothesis-driven.

بروتوكول الجرعة

FOXO4-DRI

2x/week· subcutaneous

قراءة المزيد عن FOXO4-DRI →

5,000 mcg

كل جرعة

NAD+ (IV)

Once per week· intravenous

قراءة المزيد عن NAD+ (IV) →

500,000 mcg

كل جرعة

الأهداف والدليل

Senescent cell clearanceNAD levelsCellular energyAnti-agingSenolytic
درجة الدليل:دراسات الحيوانات

تحذيرات

  • FOXO4-DRI is highly experimental with no human trials. NAD+ IV therapy is widely available but expensive. This is a cutting-edge research stack.

Comments

Sign in to join the discussion

تحذير: هذا الكود مقدم من قبل المجتمع ويهدف لغرض البحث فقط. لا يتحقق Peptide Contacts من سلامة أو فعالية الأكواد المقدمة. استشر محترف صحي مؤهل قبل استخدام أي بروتوكول بروتيني.